EW - Edwards Lifesciences Corporation
| Previous Close | 83.48 |
| Open | 83.48 |
| Bid | 83.76 x 800 |
| Ask | 83.77 x 800 |
| Day's Range | 83.04 - 84.32 |
| 52 Week Range | 67.13 - 107.92 |
| Volume | |
| Avg. Volume | 2,903,371 |
| Market Cap | 50.942B |
| Beta (5Y Monthly) | 1.02 |
| PE Ratio (TTM) | 35.61 |
| EPS (TTM) | 2.36 |
| Earnings Date | Jul 26, 2023 - Jul 31, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 94.20 |
ZacksHere's Why You Should Invest in Edward Lifesciences (EW) Now
Investors continue to be optimistic about Edward Lifesciences (EW) on the strength of the Surgical Structural Heart business and the Critical Care segment.
Simply Wall St.Edwards Lifesciences' (NYSE:EW) five-year total shareholder returns outpace the underlying earnings growth
Stock pickers are generally looking for stocks that will outperform the broader market. And the truth is, you can make...
ZacksEdwards Lifesciences (EW) Down 5.9% Since Last Earnings Report: Can It Rebound?
Edwards Lifesciences (EW) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Simply Wall St.
Edwards Lifesciences Corporation (NYSE:EW) Shares Could Be 35% Above Their Intrinsic Value Estimate
Key Insights Using the 2 Stage Free Cash Flow to Equity, Edwards Lifesciences fair value estimate is US$60.49 Edwards...
ZacksTop Stock Reports for Home Depot, Linde & Walt Disney
Today's Research Daily features new research reports on 16 major stocks, including The Home Depot, Inc. (HD), Linde plc (LIN) and The Walt Disney Company (DIS).
ZacksEdwards Lifesciences' (EW) TAVR Study Outcome Favorable
Edwards Lifesciences' (EW) latest findings of the study confirm the value of the Edwards Benchmark programme for standardizing clinical pathways for patients undergoing TAVR in Europe.
ZacksITGR vs. EW: Which Stock Is the Better Value Option?
ITGR vs. EW: Which Stock Is the Better Value Option?
ZacksSTERIS (STE) Q4 Earnings Beat Estimates, Gross Margin Falls
Heading into fiscal 2024, STERIS (STE) expects many of its fiscal 2023 challenges to abate, including procedure volumes and supply chain constraints.
ZacksHaemonetics (HAE) Q4 Earnings and Revenues Top Estimates
Amid a challenging economic environment, Haemonetics (HAE) delivers impressive fiscal fourth-quarter organic revenues, led by the stellar performance across the Plasma and Hospital business.
ZacksAlcon (ALC) Q1 Earnings Surpass Estimates, 23' EPS View Up
Alcon (ALC) Q1 revenues were driven by strong consumables and equipment sales.
ZacksHere's Why You Should Retain Walgreens Boots (WBA) For Now
Investors are optimistic about Walgreens Boots (WBA) on consistent partnership growth and a strong focus on strategic execution.
ZacksCharles River (CRL) Q1 Earnings Top Estimates, View Narrowed
Charles River (CRL) registers robust growth in small research models, research model services and the Cell Solutions business.
ZacksNuVasive (NUVA) Q1 Earnings Beat Estimates, Margins Fall
NuVasive's (NUVA) strong sales across the U.S. Spinal Hardware and U.S. Surgical Support businesses instill optimism.
ZacksSyneos Health (SYNH) Tops Q1 Earnings, Announces Merger Plan
Syneos Health's (SYNH) first-quarter 2023 earnings and revenues beat estimates. The company enters into a definitive merger agreement to be acquired by a private investment consortium.
- Zacks
SmileDirectClub (SDC) Q1 Earnings Miss, Gross Margin Up
SmileDirectClub (SDC) Q1 revenues are affected by persistent macroeconomic headwinds.
ZacksExact Sciences (EXAS) Q1 Earnings Top, Sales View Raised
The upside in Exact Sciences' (EXAS) screening revenues is primarily coming from broad-based momentum in Cologuard adoption.
ZacksHenry Schein (HSIC) Q1 Earnings Miss, Operating Margin Dips
Henry Schein's (HSIC) first-quarter results largely reflect lower contributions from the sales of PPE products and COVID-19 test kits.
ZacksOmnicell's (OMCL) New Acquisitions Aid Growth, Cost Woes Stay
Omnicell (OMCL) remains well-positioned to meet pharmacy and hospital needs, backed by the recent acquisitions and expansion of its advanced services solutions.
- Zacks
Bruker's (BRKR) New Buyout to Advance Digital Transformation
Bruker's (BRKR) IDS division expands its unique vendor-agnostic software solutions portfolio by integrating ZONTAL with the Mestrelab Research and Arxspan scientific software solutions.
ZacksHere's Why You Should Retain Abbott (ABT) Stock For Now
Investors are optimistic about Abbott (ABT) on continued growth in the core Diagnostics arm.
- Zacks
Teleflex (TFX) Q1 Earnings Top Estimates, 2023 Sales View Up
Teleflex (TFX) registers growth across the majority of its businesses, including double-digit increases in interventional and surgical revenues in Q1.
- Investing.com
InvestingPro exclusive: Vertex is a Biotech Beast + 4 More Poised to Soar
Here is your VIP list of Pro Picks for the week, offered exclusively to InvestingPro subscribers: a hand-picked selection of S&P 500 stocks that InvestingPro awarded a high financial health score of at least 2.75 out of 5.00.
ZacksGlobus Medical (GMED) Q1 Earnings Beat, Operating Margin Dips
The significant year-over-year surge in Globus Medical's (GMED) Enabling Technologies sales is driven by ongoing demand for the company's robotics and imaging system technologies.
ZacksInsulet (PODD) Q1 Earnings Beat Estimates, Sales View Up
Omnipod 5 continues to be a driving force of Insulet's (PODD) strong U.S. growth, representing almost 95% of U.S. new customer starts in the first quarter.
ZacksBruker (BRKR) Tops Q1 Earnings Estimates, Raises '23 Outlook
Bruker (BRKR) delivers a year-over-year revenue increase across all its segments in the first quarter, led by the strong demand for differentiated, high-performance scientific instruments and life-science solutions.
